Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Samjin Pharmaceuticals Co., Ltd. (005500.KS)
Seoul, KR
Samjin Pharmaceuticals Co., Ltd. is a South Korean company focused on the discovery and development of pharmaceutical products. Their current portfolio includes SA001, a Phase II clinical asset targeting dry eye and Sjögren's syndrome. In the preclinical stage, they are advancing SJP1803/1804 for macular degeneration, alongside SJP601 and SJP1602, which are designed to combat cancer. Additionally, SPJ1604 and SPJ003 are in clinical phases for treating cancer and diabetes. A broader range of candidates, including SJP1901, SJP1902, SJP1801, and SJP006, are undergoing biological testing for potential applications across cancer, fibrosis, cancer immunotherapy, Alzheimer's disease, Parkinson's disease, and anti-viral conditions. The company was founded in 1968 and is based in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.83% | +21.23% | +14.88% | +10.66% | +8.23% | +12.26% | +24.50% | -6.26% | -16.22% | -29.20% | +328.85% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.3% Q1'26: -3.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-36.9% Q1'26: -63.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.8% Q1'26: +15.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.0% Q1'26: +5.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.0% Q1'26: +2.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-2.9% ★ Q1'26: +3.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.05× Q1'26: 3.36× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
216.51B
est: 216.90B (-0.2%)
|
239.31B
est: 216.90B (+10.3%)
|
245.27B
est: 240.05B (+2.2%)
|
260.02B
est: 247.00B (+5.3%)
|
241.93B
est: 257.40B (-6.0%)
|
235.16B
est: 250.40B (-6.1%)
|
250.07B
est: 252.90B (-1.1%)
|
274.03B
est: 262.00B (+4.6%)
|
292.13B
est: 294.00B (-0.6%)
|
308.35B
est: 305.20B (+1.0%)
|
309.13B
est: 315.70B (-2.1%)
|
330.70B
330.70B – 330.70B
+4.8% YoY
|
340.90B
340.90B – 340.90B
+3.1% YoY
|
| EBITDA |
42.05B
est: 34.96B (+20.3%)
|
46.29B
est: 34.96B (+32.4%)
|
53.25B
est: 38.69B (+37.7%)
|
66.34B
est: 39.81B (+66.7%)
|
27.58B
est: 41.48B (-33.5%)
|
39.36B
est: 40.35B (-2.5%)
|
42.41B
est: 40.76B (+4.1%)
|
36.81B
est: 42.22B (-12.8%)
|
36.60B
est: 47.38B (-22.8%)
|
65.92B
est: 48.53B (+35.8%)
|
44.50B
est: 50.20B (-11.3%)
|
52.58B
52.58B – 52.58B
+4.8% YoY
|
54.21B
54.21B – 54.21B
+3.1% YoY
|
| EBIT |
35.51B
est: 26.01B (+36.5%)
|
39.37B
est: 26.01B (+51.4%)
|
46.62B
est: 28.79B (+61.9%)
|
59.24B
est: 29.62B (+100.0%)
|
21.90B
est: 30.87B (-29.1%)
|
32.87B
est: 30.03B (+9.5%)
|
35.05B
est: 30.33B (+15.6%)
|
26.99B
est: 31.42B (-14.1%)
|
19.98B
est: 35.26B (-43.3%)
|
48.52B
est: 33.22B (+46.0%)
|
24.68B
est: 34.36B (-28.2%)
|
36.00B
36.00B – 36.00B
+4.8% YoY
|
37.11B
37.11B – 37.11B
+3.1% YoY
|
| Net Income |
27.04B
est: 23.95B (+12.9%)
|
30.17B
est: 23.95B (+26.0%)
|
35.80B
est: 27.96B (+28.0%)
|
25.53B
est: 32.45B (-21.3%)
|
11.88B
est: 32.61B (-63.6%)
|
27.88B
est: 23.72B (+17.5%)
|
28.40B
est: 30.28B (-6.2%)
|
21.89B
est: 16.57B (+32.1%)
|
18.91B
est: 22.76B (-16.9%)
|
39.23B
est: 34.20B (+14.7%)
|
24.17B
est: 19.75B (+22.4%)
|
22.02B
22.02B – 22.02B
+11.5% YoY
|
20.73B
20.73B – 20.73B
-5.8% YoY
|
| SGA |
45.98B
est: 30.84B (+49.1%)
|
46.43B
est: 30.84B (+50.6%)
|
45.71B
est: 34.13B (+33.9%)
|
39.78B
est: 35.12B (+13.3%)
|
28.60B
est: 36.60B (-21.9%)
|
33.02B
est: 35.60B (-7.2%)
|
34.76B
est: 35.96B (-3.3%)
|
42.71B
est: 37.25B (+14.7%)
|
41.46B
est: 41.80B (-0.8%)
|
41.21B
est: 34.82B (+18.4%)
|
—
est: 36.02B (-100.0%)
|
37.73B
37.73B – 37.73B
+4.8% YoY
|
38.89B
38.89B – 38.89B
+3.1% YoY
|
| EPS |
2,172.00
est: 1,898.67 (+14.4%)
|
2,423.00
est: 1,898.67 (+27.6%)
|
2,891.00
est: 2,217.00 (+30.4%)
|
2,075.29
est: 2,572.67 (-19.3%)
|
917.07
est: 2,585.33 (-64.5%)
|
2,266.09
est: 1,881.00 (+20.5%)
|
2,308.75
est: 2,401.00 (-3.8%)
|
1,727.82
est: 1,314.00 (+31.5%)
|
1,460.00
est: 1,805.00 (-19.1%)
|
3,110.66
est: 2,791.00 (+11.5%)
|
1,962.68
est: 1,612.00 (+21.8%)
|
1,797.00
1,797.00 – 1,797.00
+11.5% YoY
|
1,692.00
1,692.00 – 1,692.00
-5.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.01% | 51.1K | 0.15% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 37.6K | 0.46% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 11.2K | 0.44% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 132.7K | 0.39% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 71.2K | 0.29% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 55.6K | 0.28% |
| 7 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 289.84 | 0.56% |
| 8 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 22.2K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ji-hyeon Choi | Chief Executive Officer & Director | — | — |
| Kyu Seok Cho | Chairman & Chief Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 005500.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
